title: Seizure control in a patient with Dravet syndrome and cystic fibrosis.
abstract: Satisfactory treatment of patients with Dravet syndrome (DS) is often difficult. Some success can be achieved with bromides, but cognitive side effects and disturbed vigilance may limit their use. Here, we present the case of a successfully treated patient with DS and remarkable features in the course of his disease: additionally to DS, the patient was diagnosed with cystic fibrosis (CF), another genetic channelopathy. Seizure freedom could be achieved under treatment with potassium bromide at the age of 15, but at the age of 20, adverse events made it necessary to stop bromide treatment. After conversion to valproic acid, the patient remained seizure-free, and neuropsychological tests demonstrated sustained improvement of cognition.
authors: Department of Neurology, Christian-Albrechts-University of Kiel, Arnold-Heller-Str. 3, Haus 41, 24105 Kiel, Germany.
authors: Barbara
authors: B
authors: Schmalbach
authors: Department of Neurology, Christian-Albrechts-University of Kiel, Arnold-Heller-Str. 3, Haus 41, 24105 Kiel, Germany.
authors: Bettina
authors: B
authors: Moeller
authors: Department of Neuropediatrics, Christian-Albrechts-University of Kiel, Arnold-Heller-Str. 3, Haus 9, 24105 Kiel, Germany.
authors: Sarah
authors: S
authors: von Spiczak
authors: Department of Neuropediatrics, Christian-Albrechts-University of Kiel, Arnold-Heller-Str. 3, Haus 9, 24105 Kiel, Germany.
authors: Hiltrud
authors: H
authors: Muhle
authors: Department of Neuropediatrics, Christian-Albrechts-University of Kiel, Arnold-Heller-Str. 3, Haus 9, 24105 Kiel, Germany.
authors: Ulrich
authors: U
authors: Stephani
authors: Department of Neurology, Christian-Albrechts-University of Kiel, Arnold-Heller-Str. 3, Haus 41, 24105 Kiel, Germany.
authors: Nicolas
authors: N
authors: Lang
keywords: Bromide; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; Cystic fibrosis; DS, Dravet syndrome; Dravet syndrome; GABA, γ-aminobutyric acid; SCN1A, neuronal voltage-gated sodium channel subunit type 1; SMEI, severe myoclonic epilepsy of infancy; TAP, Tests of Attentional Performance; TMT A, Trail Making Test